JP2020518627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518627A5 JP2020518627A5 JP2019560299A JP2019560299A JP2020518627A5 JP 2020518627 A5 JP2020518627 A5 JP 2020518627A5 JP 2019560299 A JP2019560299 A JP 2019560299A JP 2019560299 A JP2019560299 A JP 2019560299A JP 2020518627 A5 JP2020518627 A5 JP 2020518627A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502391P | 2017-05-05 | 2017-05-05 | |
| US62/502,391 | 2017-05-05 | ||
| US201862624273P | 2018-01-31 | 2018-01-31 | |
| US62/624,273 | 2018-01-31 | ||
| PCT/US2018/030909 WO2018204661A1 (en) | 2017-05-05 | 2018-05-03 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020518627A JP2020518627A (ja) | 2020-06-25 |
| JP2020518627A5 true JP2020518627A5 (enExample) | 2021-07-26 |
| JPWO2018204661A5 JPWO2018204661A5 (enExample) | 2022-08-12 |
| JP7295034B2 JP7295034B2 (ja) | 2023-06-20 |
Family
ID=64016681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560299A Active JP7295034B2 (ja) | 2017-05-05 | 2018-05-03 | 癌関連障害の治療のためのキナゾリン－ピリジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11045472B2 (enExample) |
| EP (1) | EP3618829B1 (enExample) |
| JP (1) | JP7295034B2 (enExample) |
| CN (1) | CN110612100B (enExample) |
| ES (1) | ES2953349T3 (enExample) |
| PL (1) | PL3618829T3 (enExample) |
| TW (1) | TWI789393B (enExample) |
| UY (1) | UY37725A (enExample) |
| WO (1) | WO2018204661A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3634417T3 (pl) * | 2017-05-17 | 2023-09-25 | Arcus Biosciences, Inc. | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem |
| CN109293586A (zh) * | 2018-11-22 | 2019-02-01 | 云南师范大学 | 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法 |
| WO2020146563A1 (en) * | 2019-01-10 | 2020-07-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy |
| US12453738B2 (en) | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| TWI879779B (zh) * | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| BR112022014962A2 (pt) * | 2020-01-30 | 2022-09-20 | Ona Therapeutics S L | Terapia de combinação para tratamento de câncer e metástase de câncer |
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| AU2021284273A1 (en) | 2020-06-02 | 2022-12-15 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
| WO2021257643A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| TW202313603A (zh) | 2021-05-21 | 2023-04-01 | 美商阿克思生物科學有限公司 | Axl抑制劑化合物 |
| JP2024521706A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ化合物 |
| AU2022376961A1 (en) | 2021-10-29 | 2024-05-16 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| JP2025516262A (ja) | 2022-05-02 | 2025-05-27 | アーカス バイオサイエンシズ インコーポレイティド | 抗ｔｉｇｉｔ抗体及びその使用 |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| AU2023364215A1 (en) | 2022-10-20 | 2025-04-24 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119462487A (zh) * | 2023-08-08 | 2025-02-18 | 重庆博腾制药科技股份有限公司 | 一种阿培利司中间体4-甲基吡啶类化合物的制备方法 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| TW202517260A (zh) | 2023-10-06 | 2025-05-01 | 美商阿克思生物科學有限公司 | Ｃｂｌ—ｂ抑制劑及其使用方法 |
| WO2025096979A1 (en) | 2023-11-02 | 2025-05-08 | Arcus Biosciences, Inc. | Thiazole compounds as kit inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2289116T3 (es) | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
| TWI330183B (enExample) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| PT1622908E (pt) | 2003-05-06 | 2008-11-14 | Cv Therapeutics Inc | Derivados de xantina como antagonistas do receptor a2b de adenosina |
| AU2004299461A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| TW200813056A (en) * | 2006-06-29 | 2008-03-16 | King Pharmaceuticals Res Dev Inc | Adenosine A2B receptor antagonists |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| US8871744B2 (en) * | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| WO2016126570A1 (en) | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
-
2018
- 2018-05-03 WO PCT/US2018/030909 patent/WO2018204661A1/en not_active Ceased
- 2018-05-03 EP EP18794742.9A patent/EP3618829B1/en active Active
- 2018-05-03 US US16/610,812 patent/US11045472B2/en active Active
- 2018-05-03 PL PL18794742.9T patent/PL3618829T3/pl unknown
- 2018-05-03 CN CN201880029680.6A patent/CN110612100B/zh active Active
- 2018-05-03 JP JP2019560299A patent/JP7295034B2/ja active Active
- 2018-05-03 ES ES18794742T patent/ES2953349T3/es active Active
- 2018-05-04 TW TW107115270A patent/TWI789393B/zh active
- 2018-05-04 UY UY0001037725A patent/UY37725A/es not_active Application Discontinuation